It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Given the increasing exploration of fluorescent tracers in the field of nuclear medicine, a need has risen for practical development guidelines that can help improve the translation aspects of fluorescent tracers. This editorial discusses the does and don’ts in developing fluorescence tracers. It has been put forward by the European Association of Nuclear Medicine (EANM) Translational Molecular Imaging & Therapy committee and has been approved by the EANM board.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Interventional Molecular Imaging Laboratory, Department of Radiology, Leiden University Medical Center, Leiden, the Netherlands (GRID:grid.10419.3d) (ISNI:0000000089452978)
2 University of Oxford, Department of Oncology, CRUK&MRC Oxford Institute for Radiation Oncology, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948)
3 University Hospital Basel, Department of Nuclear Medicine, Basel, Switzerland (GRID:grid.410567.1)
4 Nuclear Medicine and Molecular Imaging Unit, Veneto Institute of Oncology IOV – IRCCS, Padua, Italy (GRID:grid.419546.b) (ISNI:0000 0004 1808 1697)
5 Université d’Angers, Université de Nantes, CRCINA, INSERM, CNRS, Nantes, France (GRID:grid.4817.a)
6 University Federico II, Department of Advanced Biomedical Sciences, Naples, Italy (GRID:grid.4691.a) (ISNI:0000 0001 0790 385X)
7 In vivo Cellular and Molecular Imaging Lab (ICMI)-Department, Vrije Universiteit Brussel, Ixelles, Belgium (GRID:grid.8767.e) (ISNI:0000 0001 2290 8069)
8 Department of Radiology & Nuclear Medicine, Erasmus Medical Centre, Rotterdam, the Netherlands (GRID:grid.5645.2) (ISNI:000000040459992X)